Glomerular Diseases Dependent on Complement Activation, Including Atypical Hemolytic Uremic Syndrome, Membranoproliferative Glomerulonephritis, and C3 Glomerulopathy: Core Curriculum 2015
about
Reclassification of membranoproliferative glomerulonephritis: Identification of a new GN: C3GNCritical appraisal of eculizumab for atypical hemolytic uremic syndromeComplement in disease: a defence system turning offensiveAnti-complement-factor H-associated glomerulopathies.Can eculizumab be discontinued in aHUS?: Case report and review of the literatureMonitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders.Atypical Hemolytic Uremic Syndrome: A Brief Review.A haplotype in CFH family genes confers high risk of rare glomerular nephropathies.Distinct roles for the complement regulators factor H and Crry in protection of the kidney from injury.Complement related kidney diseases: Recurrence after transplantation.Association among Complement Factor H Autoantibodies, Deletions of CFHR, and the Risk of Atypical Hemolytic Uremic Syndrome.Analysis of Linear Antibody Epitopes on Factor H and CFHR1 Using Sera of Patients with Autoimmune Atypical Hemolytic Uremic Syndrome.Protection of host cells by complement regulators.Severe active C3 glomerulonephritis triggered by immune complexes and inactivated after eculizumab therapy.Gain of function mutant of complement factor B K323E mimics pathogenic C3NeF autoantibodies in convertase assays.The renaissance of complement therapeutics.Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 Glomerulopathies/Immune Complex-Mediated Membranoproliferative GN.Understanding AMD by analogy: systematic review of lipid-related common pathogenic mechanisms in AMD, AD, AS and GN.Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation.Reversal of threatening blindness after initiation of eculizumab in Purtscher-like retinopathy secondary to atypical hemolytic uremic syndrome.The MFHR1 Fusion Protein Is a Novel Synthetic Multitarget Complement Inhibitor with Therapeutic Potential.Functional Characterization of the Disease-Associated N-Terminal Complement Factor H Mutation W198R.Overactivity of Alternative Pathway Convertases in Patients With Complement-Mediated Renal Diseases.Chronic kidney diseaseTherapeutic Plasma Exchange in Neonates and Infants: Successful Use of a Miniaturized MachineComplement-mediated renal diseases after kidney transplantation - current diagnostic and therapeutic options in and recurrent diseasesBe on Target: Strategies of Targeting Alternative and Lectin Pathway Components in Complement-Mediated Diseases
P2860
Q26741542-B8EBF2F9-0E36-4583-8C6F-37CDCD657F89Q26750692-4D74A441-1046-4A5B-82F9-3D6B206DCBF2Q33432423-B8B5DB0A-314A-446B-AFA3-C7D8B11841A7Q33434103-7EB7F57F-9E98-4738-85A7-B79E903680EAQ33434378-516EBD5C-B5CE-4F97-9538-B700E9B8C280Q33436307-132B6F64-638C-46C2-98CA-7FC6CBB4C351Q33442794-5F30B7CC-86F6-4ABF-95F4-96BD08817BB7Q33920982-2551522E-0982-433A-8AE8-44FA864CB0F5Q37017177-96C30C7F-A6BC-490F-82BF-36976F282B0FQ37522557-A8A38078-64A3-4E3C-A725-2D122F0A305CQ37546464-FBC449C7-E47D-46E6-80CE-7B8FC68DD8D5Q37727489-3C97A868-F0D6-48B2-98A8-E34520BBB339Q38991019-C22BC510-25C3-470A-B6E1-87B0E4C79D44Q41373365-9A71B603-161F-427C-93EA-0E9ECB3ED6E9Q47225530-5CF975BE-68BD-48E0-8737-6BD0134EAE90Q47336749-95BB5145-A6CB-4A48-874A-54AEE5DD0A41Q47650832-CD0497BD-69F0-4759-9334-EFEE50F56016Q47751388-3B2121E1-5E9B-490B-9B86-4E7428775324Q48114152-DF2C0371-6CBC-4E0C-A790-2CFC238F9525Q48147152-031A8444-67FC-49E4-8F30-86994BF094B6Q48241051-D3C02B1B-384D-46E1-9A35-FBB83F9FB1E8Q50100348-9D7608FE-91B2-40D4-8878-22D8EBFE1E6CQ52316335-7CA1505E-798E-4C85-AD1B-775D617D6B63Q57701181-29CDF67B-0BA5-4074-BB2F-3F2C8FFDDA8FQ57701332-66059EDC-5D66-4BC5-B680-3EC466DFC006Q58120548-AE8FFDAD-0150-4AAA-BE5C-6B5F4EC89874Q58795472-4565781F-EB74-4139-9F2D-F623064E1A10
P2860
Glomerular Diseases Dependent on Complement Activation, Including Atypical Hemolytic Uremic Syndrome, Membranoproliferative Glomerulonephritis, and C3 Glomerulopathy: Core Curriculum 2015
description
2015 nî lūn-bûn
@nan
2015 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Glomerular Diseases Dependent ...... ulopathy: Core Curriculum 2015
@ast
Glomerular Diseases Dependent ...... ulopathy: Core Curriculum 2015
@en
type
label
Glomerular Diseases Dependent ...... ulopathy: Core Curriculum 2015
@ast
Glomerular Diseases Dependent ...... ulopathy: Core Curriculum 2015
@en
prefLabel
Glomerular Diseases Dependent ...... ulopathy: Core Curriculum 2015
@ast
Glomerular Diseases Dependent ...... ulopathy: Core Curriculum 2015
@en
P921
P1476
Glomerular Diseases Dependent ...... ulopathy: Core Curriculum 2015
@en
P2093
Marina Noris
P304
P356
10.1053/J.AJKD.2015.03.040
P577
2015-05-29T00:00:00Z
2015-08-01T00:00:00Z